The quinolinic acid hypothesis in Huntington's chorea

Area of Science:

• Neuroscience
• Neurobiology
• Neurodegenerative diseases

Background:

• Huntington's disease (HD) is characterized by significant cell loss in the central nervous system, particularly the striatum.
• Animal models of HD utilize intrastriatal injections of excitatory amino acids (EAAs) to mimic disease pathology.
• Excitotoxicity, the degeneration of cells due to prolonged stimulation of EAA receptors, is a key mechanism.

Purpose of the Study:

• To evaluate the potential role of quinolinic acid in the etiology of Huntington's disease.
• To investigate quinolinic acid as a potential excitotoxin contributing to neurodegeneration in HD.

Main Methods:

• Review of existing studies on EAA receptors and excitotoxicity.
• Analysis of the role of quinolinic acid as an N-methyl-D-aspartate (NMDA) receptor agonist.
• Examination of controversial indications for altered quinolinic acid formation in HD brains.

Main Results:

• Quinolinic acid is identified as a metabolite of tryptophan and an agonist of the NMDA receptor.
• Quinolinic acid demonstrates potent excitotoxic properties.
• Controversial evidence suggests potential derangements in quinolinic acid formation in Huntington's disease patients.

Conclusions:

• Quinolinic acid's excitotoxic nature and its action on NMDA receptors suggest a plausible role in the pathogenesis of Huntington's disease.
• Further research is warranted to clarify the precise involvement of quinolinic acid in HD etiology.
• Understanding excitotoxicity mechanisms is crucial for developing therapeutic strategies for neurodegenerative disorders like HD.